39results about How to "Eliminate drug resistance" patented technology

The invention relates to an anti-helicobacter pylori oral preparation. The anti-helicobacter pylori oral preparation is prepared from, by weight, 6-12 parts of anti-helicobacter pylori egg yolk immunoglobulin, 2-5 parts of lactoferrin and 2-5 parts of chlorophyll in barley green. According to the anti-helicobacter pylori oral preparation, helicobacter pylori infection can be cured under the condition that no antibiotic is used, therefore, the cure rate is increased, the possibility that a pathogen generates drug resistance and the potential of relapse after curing are eliminated, and meanwhile the adverse effect rate is greatly decreased.

A slow-releasing tablet of isosorbide mononitrate for treating coronary heart disease and angina pectoris is prepared proportionally from isosorbide mononitrate, slow releasing agent, adhesive, filler and lubricant through proportional mixing, granulating, and tabletting.

The invention provides a chemical processing method of coal chemical industry recycled circulating cooling water. An agentia is composed of composite scale and corrosion inhibitor which is composed of 9-11 parts of polyepoxysuccinic acid, 18-22 parts of 2-phosphonobutane-1,2,4-tricarboxylic acid, 19-21 parts of methylene phosphonic acid, 25-35 parts of dirt dispersion agent, 1-3 parts of benzotriazole, and 9-18 parts of deionized water. First, adding polyepoxysuccinic acid into the 2-phosphonobutane-1,2,4-tricarboxylic acid, placing the polyepoxysuccinic acid and the 2-phosphonobutane-1,2,4-tricarboxylic acid in a container and evenly mixing, sequentially adding the methylene phosphonic acid, the dirt dispersion agent and the deionized water into the container, then stirring for 25-35 minutes, keeping the temperature at 20-35 DEG C, then adding the benzotriazole, continuously stirring for 30-60 minutes and keeping the temperature at 20-35 DEG C, and then, the composite scale and corrosion inhibitor is obtained. Dosage of the composite scale and corrosion inhibitor is 10mg / L, based on middle warmer strengthening water, total phosphorus of the circulating water is controlled to be 4-7mg / L, and a concentration ratio is controlled to be 5.0-6.0 times. The method further comprises sterilization and algae removing process and optimization of the circulating water.

The invention relates to an anti-tumor compound based on activating JWA gene and degrading HER2, its preparation method and application. The antitumor compound is a compound of formula I. The preparation method is to use two compounds to synthesize the compound of formula I through one-step reaction. The use is for preparing JWA gene activators or antitumor drugs. The antitumor compound of the present invention and its pharmaceutically acceptable salt can effectively activate the expression of JWA protein, and further specifically degrade the overexpressed HER2 protein through cascade activation of E3 ubiquitinase, thereby inhibiting the proliferation and growth of tumor cells in vivo.

The invention provides a bispecific antibody capable of resisting human epidermal growth factor receptor 2 (HER2) and human insulin-like growth factor-IR (IGF-IR), and a preparation method and applications thereof. The bispecific antibody comprises a first antigen binding domain used for specific binding of HER2, and a second antigen binding domain used for specific binding of IGF-IR; the first antigen binding domain and the second antigen binding domain both comprise an antibody heavy chain variable structural domain (VH) and an antibody light chain variable structural domain (VL); the first antigen binding domain is an antibody variable structural domain capable of realizing specific binding with HER2; and the second antigen binding domain is an antibody variable structural domain capable of realizing specific binding with IGF-IR. The preparation method comprises following steps: synthesis of cDNA sequences used for coding the bispecific antibody; the cDNA sequences are inserted into a carrier for construction of an expression vector; expression of the expression vector is realized in host cells, and the bispecific antibody obtained by expression is separated and purified. The bispecific antibody can be used for preparing medicines used for treating human cancer, especially human breast cancer.

The application provides a drug for inhibiting brain tumors and its application. Wherein, the drug for inhibiting brain tumors includes at least one TRPV4 agonist capable of promoting calcium ion influx of TRPV4 signaling channel. The medicine provided by the application has a good therapeutic effect on brain tumors and related diseases, and has good application prospects for the treatment of brain tumors and related diseases. The medicine provided by the application is applied to medicines for treating brain tumors and related diseases, which can reduce the toxic and side effects produced in the clinical treatment of brain tumors and related diseases, and improve the therapeutic effect of brain tumors and related diseases.

A target medicine for treating bacterial disease features that its active component is a conjugate of the antibacterial serum antibody and antibiotic, and the target medicine can move toward bacteria, resulting in high effect. Its preparing process is also disclosed.

The present application provides an application of a drug in the preparation of a drug for the treatment of brain metastases-related diseases, wherein the drug includes at least one TRPV4 agonist capable of promoting calcium ion influx of TRPV4 signaling channels, the brain metastases and Related diseases include brain metastases, diseases arising during the formation of brain metastases, complications and sequelae caused by brain metastases, and diseases related to brain metastases. Applying the above-mentioned medicine to the preparation of medicines for treating diseases related to brain metastases can play a significant anti-tumor effect through a clear mechanism of action, with good therapeutic effects and good application prospects.